Physician profile
Weiwei Dai
NPI 1417248469
$366,754.91
in general payments reported to CMS, 2019-2025
50 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,977 · 2020: $10K · 2021: $86K · 2022: $52K · 2023: $55K · 2024: $57K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Travel and Lodging: $22K · Food and Beverage: $21K · Honoraria: $16K · Consulting Fee: $13K · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,843.75 |
| Travel and Lodging | $22,414.05 |
| Food and Beverage | $21,278.00 |
| Honoraria | $16,105.00 |
| Consulting Fee | $13,186.88 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192,529.80 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $38,826.60 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Pfizer INC. | $36,852.32 | 2023-2025 | |
| Lundbeck LLC | $26,860.27 | 2022-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $23,227.03 | 2021 | |
| Allergan, INC. | $15,626.95 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14,294.55 | 2022 | |
| Livanova USA, INC. | $3,757.49 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $1,791.08 | 2019-2025 | |
| Emd Serono, INC. | $1,623.88 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,085.48 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Genzyme Corporation | $834.32 | 2019-2023 | |
| Eisai INC. | $758.41 | 2022-2025 | |
| Ucb, INC. | $596.44 | 2019-2025 | Zilbrysq, Rystiggo |
| Biogen, INC. | $583.07 | 2019-2025 | Tysabri, Tysabri, Vumerity |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $490.50 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $447.56 | 2022-2025 | |
| Genentech USA, INC. | $445.87 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $444.70 | 2019-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $410.37 | 2023-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals Lp | $338.24 | 2024-2025 | Wainua |
| Csl Behring | $330.49 | 2021-2025 | Hizentra, Privigen |
| Neurocrine Biosciences, INC. | $328.84 | 2019-2025 | Ingrezza |
| Genentech, INC. | $315.17 | 2023-2025 | Ocrevus, Enspryng |
| Otsuka America Pharmaceutical, INC. | $314.30 | 2023-2025 | Rexulti |
| Argenx US, INC. | $280.15 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Averitas Pharma INC. | $254.09 | 2024-2025 | Qutenza |
| Upsher-Smith Laboratories LLC | $253.58 | 2020-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $249.42 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $242.29 | 2022-2025 | |
| Horizon Therapeutics Plc | $240.93 | 2022-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $232.74 | 2024 | Zeposia |
| Abbott Laboratories | $229.56 | 2022-2023 | Infinity |
| Janssen Biotech, INC. | $194.30 | 2025 | |
| Microtransponder, INC. | $168.82 | 2024 | |
| Merz Pharmaceuticals, LLC | $153.93 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $153.33 | 2023-2025 | Gammagard, Hyqvia |
| Amneal Pharmaceuticals LLC | $144.46 | 2025 | Crexont, Ongentys |
| Neurelis, INC. | $133.61 | 2024-2025 | Valtoco |
| Impel Pharmaceuticals INC. | $132.47 | 2023 | Trudhesa |
| Sunovion Pharmaceuticals INC. | $111.70 | 2021 | |
| C2n Diagnostics, LLC | $110.51 | 2025 | Precivityad2 |
| Grifols USA, LLC | $70.12 | 2024-2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $67.25 | 2019 | |
| Tanabe Pharma America, INC. | $57.14 | 2019-2022 | |
| Tg Therapeutics, INC. | $53.71 | 2024-2025 | |
| Ge Healthcare | $37.25 | 2025 | |
| Greenwich Biosciences, INC. | $30.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.87 | 2022 | |
| Aesculap, INC. | $18.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiwei Dai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.